Bridging chemotherapy is often used to control tumor progression during this period and has been shown to enhance CAR-T efficacy by reducing immune suppressor cells in the tumor microenvironment and upregulating chemokines such as CCL5, CXCL9, and CXCL10 to improve T cell trafficking [211]. Here, CXCL9 is linked to neoplasm.